BioCentury’s data-bytes round-up highlights six first-in-class approvals in August, including Ionis’ Zanvastro for Alexander disease and AZ’s Etcamah for breast cancer. The list also signals how regulators are prioritizing novel mechanisms across rare and oncology indications. For the sector, first-in-class approvals often drive investor and competitive attention toward similar modalities, including RNA-targeting therapies and other platform-driven programs. It also provides a benchmark for how quickly new drug classes can convert into clinical adoption once evidence requirements are met. Biopharma teams will use the pattern to calibrate development plans—particularly around differentiation, endpoint selection, and the evidence thresholds needed for first-in-class status.